Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

robot
Abstract generation in progress

Morgan Stanley has lowered its price target for IQVIA Holdings Inc. (IQV) to $240 from $265 but reiterated an Overweight rating following the company’s strong fourth-quarter 2025 results. IQVIA also announced a collaboration with Duke Clinical Research Institute to advance clinical research in obesity and cardiometabolic trials, aiming to improve trial efficiency and accelerate therapy delivery to patients. The company reported better-than-expected fourth-quarter revenue and expressed optimism for 2026 driven by expanded market efforts, operational discipline, and AI investments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin